Developing and Testing Warning Labels for Retail Cannabis Products

开发和测试零售大麻产品的警告标签

• 批准号: 10738445
• 负责人: Zachary Massey
• 金额: $ 16.17万
• 依托单位: UNIVERSITY OF MISSOURI-COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10738445
• 关键词: Adult; Affect; Attitude; Automobile Driving; Behavioral; Belief; Biological; Cancer Patient; Cannabis; Cannabis policy; Cannabis retail; Cardiovascular Diseases; Characteristics; Colorado; Consumption; Data; Development; Emotions; Ensure; Environment; Focus Groups; Future; Goals; Health; Health behavior; Impaired cognition; Intervention; Label; Learning; Legal; Literature; Lung diseases; Measures; Mentorship; Methods; Motivation; Nausea; Outcome; Outcome Study; Participant; Patient Recruitments; Perception; Poison Control Centers; Policies; Population; Product Labeling; Provider; Psychoses; Reaction; Recreation; Regulation; Reporting; Research; Research Activity; Research Methodology; Risk; Science; Scientist; Social Marketing; Source; Testing; Text; Therapeutic; Time; Tobacco Control Research; Training; Training Activity; Translating; Update; Variant; Work; addiction; adverse outcome; behavior influence; cannabis use behavior; career; design; drugged driving; experience; experimental study; follow-up; health belief; health communication; health knowledge; health warning; high risk; improved; innovation; insight; marijuana legalization; marijuana use; multiple sclerosis patient; novel; programs; psychologic; randomized, clinical trials; respiratory; risk perception; smoking cessation; spasticity; substance use; theories; therapy outcome; warning label

PROJECT ABSTRACT Despite the legalization of retail cannabis (i.e., non-medical, “recreational”) in multiple states, there are still no federal regulations for warnings on cannabis products in the U.S. This is troubling because states that legalize cannabis report increased calls to poison control centers, and cannabis consumption has been associated with cognitive impairment, deadly lung disease, and respiratory problems. At the same time, cannabis has therapeutic benefits, including reduced spasticity for multiple sclerosis patients. The fact that cannabis has adverse and therapeutic outcomes has contributed to an environment where substantial proportions of U.S. consumers both over- and under-estimate the health risks of cannabis. This highlights the need for clear, effective labeling regulations to ensure accurate risk perceptions. Despite evidence of the efficacy of health warning attributes (e.g., adding pictures to text), there is limited data on how such warning attributes influence cannabis consumers in the U.S. This proposal will inform how cannabis warning-label characteristics influence cannabis consumers’ (i.e., past 30-day use) attitudes and beliefs, intentions, and problematic cannabis use behaviors by accomplishing the following specific aims: Aim 1: Assess consumer perceptions about draft cannabis warning labels through focus groups with adult cannabis consumers (21+) from legal retail states; Aim 2: Determine how attributes of updated cannabis warning labels affect cannabis consumers’ (21+ from retail states) emotions and perceived risk using a discrete choice experiment (DCE); Aim 3: Use a randomized clinical trial (RCT) to test enhanced warning labels against the existing product labels to determine how exposure influences cannabis consumers’ (21+ from retail states) label reactions (emotion and reactance), attitudes and beliefs (perceived risks and health beliefs about cannabis), and intentions for problematic use (e.g., driving after cannabis consumption) immediately after exposure (Session 1). At 2-week follow-up (Session 2), we will measure message recall and cannabis-use behaviors in the last 2 weeks (i.e., interpersonal conversations about cannabis, cannabis use, money spent on cannabis, quitting attempts, and problematic use), and behavioral intentions (motivation to quit cannabis in 6 months). This innovative proposal includes training activities to ensure that Dr. Massey achieves the following five career goals: 1) Develop expertise in psychological and biological mechanisms of addiction; 2) Receive hands-on training for the development of cannabis warning labels; 3) Learn advanced research methods for warning label research with DCEs; 4) Acquire advanced training in RCTs; and 5) Create a sustainable line of research for future R01 submissions. The mentorship team includes experts in developing and testing warning labels (Hammond, Thrasher, Popova), substance use research (Hammond, Froeliger), cannabis policy (Hammond), mixed methods (Popova, Rodgers, Thrasher), and design of DCEs and RCTs to test consumer warnings (entire team). The proposed mentorship, training, and research activities would prepare Dr. Massey for an independent research career with a sustainable substance-use research program.

项目摘要 尽管零售大麻合法化（即非医学，“娱乐”），但仍有 美国没有关于美国大麻产品警告的法规，这令人不安 大麻报告增加了对毒物控制中心的电话，大麻消费与 认知障碍，致命的肺部疾病和呼吸系统疾病。同时，大麻进行治疗 益处，包括减少多发性硬化症患者的痉挛。大麻有广告和 治疗结果为美国消费者大量比例的环境做出了贡献 过度和低估了大麻的健康风险。这凸显了需要清晰，有效的标签 规定确保准确的风险感知。尽管有证据表明健康警告属性的效率 （例如，在文本中添加图片），关于这种警告属性如何影响大麻消费者的数据有限 在美国，该提案将告知大麻警告标签特征如何影响大麻消费者 （即过去30天的使用）参加和相信，意图和有问题的大麻使用行为 完成以下具体目标：目标1：评估消费者对大麻草案警告的看法 通过与法律零售州的成年大麻消费者（21岁以上）的焦点小组标记；目标2：确定如何 更新的大麻警告标签的属性会影响大麻消费者（零售州的21岁以上）情绪和 使用离散选择实验（DCE）感知风险；目标3：使用随机临床试验（RCT）进行测试 增强了针对现有产品标签的警告标签，以确定曝光如何影响大麻 消费者（来自零售州的21岁以上）标签反应（情感和反应），参加并相信（感知到 关于大麻的风险和健康信念）以及问题使用的意图（例如，大麻之后开车 消费）立即在暴露后（会议1）。在2周的随访（第2节），我们将测量 消息回忆和大麻使用的行为在过去2周内（即，关于人际关系的对话 大麻，大麻使用，花在大麻上的钱，安静的尝试和有问题的使用）和行为 意图（在6个月内退出大麻的动机）。该创新的建议包括培训活动以确保 Massey博士实现了以下五个职业目标：1）发展心理和生物学方面的专业知识 成瘾的机制； 2）接受大麻警告标签开发的动手培训； 3）学习 用于警告标签研究的高级研究方法； 4）接受RCT的高级培训；和 5）为未来的R01提交创建可持续的研究线。 Mentalship团队包括专家 开发和测试警告标签（Hammond，Thrasher，Popova），药物使用研究（Hammond，Hammond， 弗罗伊尔（Froliger），大麻政策（Hammond），混合方法（Popova，Rodgers，Thrasher）和DCE的设计 RCT测试消费者警告（整个团队）。拟议的精通训练，培训和研究活动将 Massey博士通过可持续的药物使用研究计划为独立研究职业做好准备。